- Home
- IQ vs NNNN Comparison
IQ vs NNNN Comparison
Compare IQ & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IQ
- NNNN
- Stock Information
- Founded
- IQ 2009
- NNNN 2021
- Country
- IQ China
- NNNN Germany
- Employees
- IQ N/A
- NNNN N/A
- Industry
- IQ Consumer Electronics/Video Chains
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- IQ Consumer Discretionary
- NNNN Health Care
- Exchange
- IQ Nasdaq
- NNNN Nasdaq
- Market Cap
- IQ 2.4B
- NNNN 2.2B
- IPO Year
- IQ 2018
- NNNN 2025
- Fundamental
- Price
- IQ $2.45
- NNNN $28.84
- Analyst Decision
- IQ Strong Buy
- NNNN
- Analyst Count
- IQ 5
- NNNN 0
- Target Price
- IQ $2.61
- NNNN N/A
- AVG Volume (30 Days)
- IQ 13.4M
- NNNN 73.9K
- Earning Date
- IQ 11-20-2025
- NNNN 10-23-2025
- Dividend Yield
- IQ N/A
- NNNN N/A
- EPS Growth
- IQ N/A
- NNNN N/A
- EPS
- IQ 0.01
- NNNN 0.06
- Revenue
- IQ $3,863,007,761.00
- NNNN $8,185,146.00
- Revenue This Year
- IQ N/A
- NNNN N/A
- Revenue Next Year
- IQ $3.85
- NNNN N/A
- P/E Ratio
- IQ $261.65
- NNNN $545.12
- Revenue Growth
- IQ N/A
- NNNN 21.95
- 52 Week Low
- IQ $1.50
- NNNN $5.18
- 52 Week High
- IQ $3.21
- NNNN $55.65
- Technical
- Relative Strength Index (RSI)
- IQ 49.59
- NNNN 35.78
- Support Level
- IQ $2.41
- NNNN $22.08
- Resistance Level
- IQ $2.51
- NNNN $51.33
- Average True Range (ATR)
- IQ 0.09
- NNNN 5.72
- MACD
- IQ -0.05
- NNNN -0.91
- Stochastic Oscillator
- IQ 17.19
- NNNN 21.32
About IQ iQIYI Inc.
Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.